FENNEC PHARMACEUTICALS INC. 8-K

What Happened
Fennec Pharmaceuticals announced on March 16, 2026 that it entered into a License Agreement with Cipla Limited and Cipla USA, Inc. to resolve ongoing litigation over Cipla’s application to the FDA to market a generic version of PEDMARK® (sodium thiosulfate injection) (Fennec v. Cipla, C.A. No. 2:23-cv-00123-JKS-MAH, D.N.J.). Under the agreement the lawsuit will be dismissed, each party will bear its own litigation costs, and Cipla has agreed not to enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under specified circumstances. Fennec issued a press release on March 16, 2026 announcing the agreement.

Key Details

• License Agreement resolves litigation captioned Fennec Pharmaceuticals Inc. v. Cipla Limited and Cipla USA, Inc., C.A. No. 2:23-cv-00123-JKS-MAH (D.N.J.).
• Product involved: PEDMARK® (sodium thiosulfate injection).
• Cipla agrees not to enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, though earlier entry is possible under specified circumstances.
• The lawsuit will be dismissed and each party will bear its own costs; announcement made via press release on March 16, 2026.

Why It Matters
For investors, the agreement reduces near-term litigation uncertainty and potentially delays generic competition to PEDMARK in the U.S. through 2033, which could preserve Fennec’s commercial opportunity for the product over that period. However, the filing notes earlier generic entry is possible under specified circumstances, so the timing and financial impact depend on the detailed terms and any triggering events (not described in the 8-K). The company furnished a press release as an exhibit to the 8-K for additional context.